| Detailed information |
|---|
| CancerLivER ID | 2457 |
| Biomarker | EHMT2 |
| Biomarker Name/Symbol (given in Publication) | EHMT2 |
| Biomolecule | RNAs |
| Subject | Human |
| Degree of Validity | Potential biomarker and therapeutic target for HCC and upregulated in highly invasive HCC than less-invasive HCC and validated on independent dataset |
| Experimental Condition | less (L) invasive HCC v/s highly (H) invasive HCC; associated with survival of patients |
| Cancer type | Hepatocellular carcinoma |
| Regulation | Upregulated in highly invasive HCC than less-invasive HCC (with fold change of 1.80 ) |
| Level of significance | p < 0.01 |
| Source | Tissue |
| PMID | 19945130 |
| Type of Biomarker | Prognostic |
| Pathway | Regulation of TP53 Activity and Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3. |
| Cohort | 188 HCC patients, 59 were selected randomly for test analyses (V0 [HCCs without vascular invasion] = 29 cases, V1 [HCCs with microvascular invasion] = 14 cases, and V2 [HCCs with macrovascular invasion] = 16 cases), and another 129 cases were evaluated for validation analyses (V0 = 67 cases, V1 = 33 |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | NA |
| AUC | NA |
| Disease | less (L) invasive HCC v/s highly (H) invasive HCC |
| Year of Publication | 2010 |
| Clinical trial | NO |
| Clinical trial (NCT Number) | NA |